[go: up one dir, main page]

NL301042I2 - Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout - Google Patents

Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout Download PDF

Info

Publication number
NL301042I2
NL301042I2 NL301042C NL301042C NL301042I2 NL 301042 I2 NL301042 I2 NL 301042I2 NL 301042 C NL301042 C NL 301042C NL 301042 C NL301042 C NL 301042C NL 301042 I2 NL301042 I2 NL 301042I2
Authority
NL
Netherlands
Prior art keywords
trifarotene
optionally
pharmaceutically acceptable
acceptable salt
salt
Prior art date
Application number
NL301042C
Other languages
English (en)
Other versions
NL301042I1 (nl
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0413848A external-priority patent/FR2880020B1/fr
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of NL301042I1 publication Critical patent/NL301042I1/nl
Publication of NL301042I2 publication Critical patent/NL301042I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
NL301042C 2004-12-23 2020-06-10 Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout NL301042I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0413848A FR2880020B1 (fr) 2004-12-23 2004-12-23 NOUVEAUX LIGANDS MODULATEURS DES RECEPTEURS RARs, UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
US64738305P 2005-01-28 2005-01-28
PCT/EP2005/014217 WO2006066978A1 (en) 2004-12-23 2005-12-21 Novel ligands that modulate rar receptors, and use thereof in human medicine and in cosmetics

Publications (2)

Publication Number Publication Date
NL301042I1 NL301042I1 (nl) 2020-06-17
NL301042I2 true NL301042I2 (nl) 2020-08-10

Family

ID=35981712

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301042C NL301042I2 (nl) 2004-12-23 2020-06-10 Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout

Country Status (11)

Country Link
EP (1) EP1831149B1 (nl)
JP (1) JP5258299B2 (nl)
KR (1) KR101316992B1 (nl)
AU (1) AU2005318292B2 (nl)
BR (1) BRPI0517500B8 (nl)
CA (1) CA2590246C (nl)
CY (2) CY1112721T1 (nl)
MX (1) MX2007007696A (nl)
NL (1) NL301042I2 (nl)
PL (1) PL1831149T3 (nl)
WO (1) WO2006066978A1 (nl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
FR2915682B1 (fr) * 2007-05-04 2009-07-03 Galderma Res & Dev Compositions depigmentantes dermatologiques et cosmetiques, leurs procedes de preparation, et leurs utilisations
AU2008326309C1 (en) 2007-11-21 2015-03-12 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
EP2222638A2 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating inflammation
FR2931661B1 (fr) 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise et un retinoide.
RU2011146363A (ru) 2009-04-16 2013-05-27 Такеда Фармасьютикал Компани Лимитед Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US9084778B2 (en) 2012-06-01 2015-07-21 Galderma Research & Development Topical compositions containing a retinoid of the oil-in-water emulsion type
FR2991174B1 (fr) * 2012-06-01 2014-12-26 Galderma Res & Dev Composition dermatologique comprenant des oleosomes et des retinoides, son procede de preparation et son utilisation
FR2991172A1 (fr) * 2012-06-01 2013-12-06 Galderma Res & Dev Compositions pharmaceutiques topiques comprenant des microcapsules
FR2991175B1 (fr) * 2012-06-01 2014-12-19 Galderma Res & Dev Compositions pharmaceutiques topiques de type emulsion h/e contenant un retinoide
FR2991176B1 (fr) * 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide solubilise, de type gel hydroglycolique
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
FR2991178B1 (fr) 2012-06-01 2014-06-27 Galderma Res & Dev Compositions topiques de type gel aqueux sous forme de suspension homogene d'un principe actif de la classe des retinoides contenant au moins une silice hydrophobe.
FR2991177B1 (fr) * 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
WO2013178749A1 (fr) 2012-06-01 2013-12-05 Galderma Research & Development Nanocapsules lipidiques comprenant un rétinoide, nanodispersion et composition les contenant, leur procédé de préparation et leur utilisation en dermatologie
ES2663478T3 (es) * 2013-05-10 2018-04-12 Basf Se Agente con elevadas cantidades de estabilizantes frente a UV
AU2014359194B2 (en) 2013-12-04 2020-02-06 Galderma Research & Development Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
EP3220903A1 (fr) * 2014-11-20 2017-09-27 Galderma S.A. Compositions comprenant un compose de la famille des avermectines et un compose agoniste d'au moins un des recepteurs de l'acide retinoique pour le traitement de l'acne
FR3028763A1 (fr) * 2014-11-20 2016-05-27 Galderma Sa Compositions comprenant un compose de la famille des avermectines et un compose antagoniste d'au moins un des recepteurs rar pour le traitement de l'acne
EP3302421B1 (fr) 2015-05-29 2021-07-07 Galderma Research & Development Compositions comprenant au moins un principe actif disperse et des microcapsules lipidiques
EP3108875A1 (en) * 2015-06-23 2016-12-28 Galderma Research & Development Compositions comprising water dispersible nanoparticles of a retinoid compound
EP4037672A1 (en) 2019-10-02 2022-08-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve
EP4073035A1 (en) * 2019-12-11 2022-10-19 Taro Pharmaceutical Industries Ltd. Preparation of trifarotene and intermediates and polymorphs thereof
CN113999117B (zh) * 2021-09-10 2023-12-08 南京迈诺威医药科技有限公司 一种联苯化合物的制备方法
CN115786366B (zh) * 2022-11-30 2024-11-29 淮阴工学院 一种茄子抗寒调控基因、蛋白及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604926D0 (en) * 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
FR2759292B1 (fr) * 1997-02-10 2000-08-11 Cird Galderma Utilisation de retinoides en tant qu'agents induisant la pigmentation
FR2763588B1 (fr) * 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
FR2767525B1 (fr) * 1997-08-21 1999-11-12 Cird Galderma Derives biphenyliques substitues par un radical aromatique ou heteroaromatique et compositions pharmaceutiques et cosmetiques les contenant

Also Published As

Publication number Publication date
WO2006066978A1 (en) 2006-06-29
CA2590246A1 (en) 2006-06-29
RU2440973C2 (ru) 2012-01-27
EP1831149B1 (en) 2012-01-25
CY1112721T1 (el) 2016-02-10
EP1831149A1 (en) 2007-09-12
BRPI0517500B8 (pt) 2021-05-25
CA2590246C (en) 2015-07-14
CY2022031I2 (el) 2023-01-05
KR101316992B1 (ko) 2013-10-11
AU2005318292A1 (en) 2006-06-29
KR20070087626A (ko) 2007-08-28
NL301042I1 (nl) 2020-06-17
RU2007127867A (ru) 2009-01-27
AU2005318292B2 (en) 2011-09-22
JP2008525364A (ja) 2008-07-17
MX2007007696A (es) 2007-08-17
JP5258299B2 (ja) 2013-08-07
PL1831149T3 (pl) 2012-06-29
CY2022031I1 (el) 2023-01-05
BRPI0517500B1 (pt) 2018-10-09
BRPI0517500A (pt) 2008-10-07

Similar Documents

Publication Publication Date Title
NL301042I2 (nl) Trifaroteen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301261I2 (nl) Gefapixant, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL301150I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301049I1 (nl) Crisaborale, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301299I2 (nl) Capivasertib, eventueel in de vorm van een farmaceutisch aanvaardbaar zout
NL300974I2 (nl) Binimetinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL300863I2 (nl) Palbociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301021I2 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
NL300946I2 (nl) Brexpiprazole, desgewenst in de vorm van een zout
NL301020I2 (nl) Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat
NL301067I2 (nl) Cefiderocol, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat
NL300913I2 (nl) Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride
NL301106I1 (nl) Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301199I2 (nl) Difelikefalin, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, hydraat, solvaat, zuurzout-hydraat of N-oxide
NL301057I2 (nl) Glasdegib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, met inbegrip van het maleaatzout
NL301256I2 (nl) cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301037I2 (nl) Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NL300909I2 (nl) Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301209I2 (nl) capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL300971I2 (nl) Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301033I2 (nl) Larotrectinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout, in het bijzonder larotrectinibsulfaat, met inbegrip van larotrectinibsulfaat monohydraat
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NL301104I2 (nl) Fedratinib, of een farmaceutisch aanvaardbaar zout daarvan, of een farmaceutisch aanvaardbaar hydraat daarvan, in het bijzonder fedratinibdihydrochloridemonohydraat.
NL301003I2 (nl) Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl) Apalutamide of een farmaceutisch aanvaardbaar zout daarvan